Mwanzo0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Bei iliyotangulia
$ 0.41
Bei za siku
$ 0.41 - $ 0.42
Bei za mwaka
$ 0.30 - $ 0.62
Thamani ya kampuni katika soko
3.94B HKD
Wastani wa hisa zilizouzwa
elfu 887.22
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
HKG
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (HKD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.32B | 2.20% |
Matumizi ya uendeshaji wa biashara | 323.51M | -4.23% |
Mapato halisi | elfu 500.50 | -97.29% |
Kiwango cha faida halisi | 0.04 | -97.20% |
Mapato kwa kila hisa | — | — |
EBITDA | 117.12M | 36.03% |
Asilimia ya kodi ya mapato | 79.96% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (HKD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 562.09M | 11.10% |
Jumla ya mali | 10.89B | -1.45% |
Jumla ya dhima | 6.87B | -0.11% |
Jumla ya hisa | 4.01B | — |
hisa zilizosalia | 9.61B | — |
Uwiano wa bei na thamani | 0.98 | — |
Faida inayotokana na mali | 1.75% | — |
Faida inayotokana mtaji | 1.91% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (HKD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | elfu 500.50 | -97.29% |
Pesa kutokana na shughuli | 72.70M | 80.63% |
Pesa kutokana na uwekezaji | -47.88M | -484.81% |
Pesa kutokana na ufadhili | -77.72M | 41.39% |
Mabadiliko halisi ya pesa taslimu | -57.56M | 42.02% |
Mtiririko huru wa pesa | 35.56M | 91.21% |
Kuhusu
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2000
Tovuti
Wafanyakazi
1,968
